A Systematic Review of Phase III Clinical Trials of Daratumumab Addition to Standard Care Regimen for Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Ahmed, Zahoor
Neupane, Karun
Ashraf, Rabia
Khan, Amna
Shahzad, Moazzam
Farooqui, Arafat Ali
Faisal, Muhammad Salman
Nabeel, Shaha
Jamil, Abdur Rehman
Anwer, Faiz
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134895
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma
    Kourelis, Taxiarchis
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Wolfe, Eric
    BLOOD, 2018, 132
  • [32] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Derman, Ben A.
    Major, Ajay
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Alcantar, Luis
    Libao, Bernadette M.
    McIver, Amanda
    Andreatos, Evangelia
    Major, Sarah
    Wolfe, Brittany
    Gorski, Martha
    Karrison, Theodore G.
    Stefka, Andrew
    Jakubowiak, Andrzej
    BLOOD, 2021, 138
  • [33] Correction to: Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Yvette N. Lamb
    Drugs, 2021, 81 : 183 - 183
  • [34] Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
    D'Agostino, Mattia
    De Paoli, Lorenzo
    Conticello, Concetta
    Offidani, Massimo
    Ria, Roberto
    Petrucci, Maria Teresa
    Spada, Stefano
    Marcatti, Magda
    Catalano, Lucio
    Gilestro, Milena
    Guglielmelli, Tommasina
    Baldini, Luca
    Gamberi, Barbara
    Rizzi, Rita
    De Sabbata, Giovanni
    Di Renzo, Nicola
    Patriarca, Francesca
    Pezzatti, Sara
    Siniscalchi, Agostina
    Ribolla, Rossella
    Palumbo, Antonio
    Montefusco, Vittorio
    Nagler, Arnon
    Boccadoro, Mario
    Gay, Francesca
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 132 : 9 - 16
  • [35] Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
    Kiss, Szabolcs
    Gede, Noemi
    Hegyi, Peter
    Nagy, Bettina
    Deak, Rita
    Dembrovszky, Fanni
    Bunduc, Stefania
    Eross, Balint
    Leiner, Tamas
    Szakacs, Zsolt
    Alizadeh, Hussain
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [36] Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
    Szabolcs Kiss
    Noémi Gede
    Péter Hegyi
    Bettina Nagy
    Rita Deák
    Fanni Dembrovszky
    Stefania Bunduc
    Bálint Erőss
    Tamás Leiner
    Zsolt Szakács
    Hussain Alizadeh
    Scientific Reports, 11
  • [37] Thalidomide and dexamethasone for newly diagnosed multiple myeloma: Is this really the standard of care? Reply
    Anderson, Kenneth C.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2968 - 2969
  • [38] A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN OF NEWLY DIAGNOSED MULTIPLE MYELOMA
    Cizova, D.
    Panjabi, S.
    Rose, D.
    Abbas, Z.
    Buchanan, J.
    Wilke, T.
    VALUE IN HEALTH, 2019, 22 : S461 - S461
  • [39] Daratumumab-Related Pulmonary Toxicities in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
    Win, Myint
    Thein, Kyaw
    Phyu, Ei
    Han, Myat
    D'Cunha, Paul
    Nelson, Joseph, III
    Quick, Donald
    Sklar, Allan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S242 - S242
  • [40] Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
    Xu, Shuiqing
    Chen, Wenming
    Li, Yanchen
    HEMATOLOGY, 2024, 29 (01)
12345